Development and evaluation of an intranasal nanoparticulate formulation for enhanced transport of Rivastigmine into the brain

Abstract

The present research work involves the formulation and development of rivastigmine and coumarin-6 loaded biodegradable Polylactide-co-glycolic acid nanoparticles attached with single and double nasal mucosa/brain targeting ligands. The developed nanocarrier systems were formulated by a solvent evaporation method and have a particle size of 189-242 nm and drug loading of 3.4%. These systems showed sustained drug release and brain targeting ability. When tested on rats via intranasal administration, 2.2 and 3.3 folds increase in brain targeting with single and dual ligands nanoparticles respectively in comparison to the drug solution. Our study supports the use of sustained release nanoparticles with dual ligands, in conjunction with intranasal administration to achieve better brain targeting efficiency.